Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.

McCarver DG, Hines RN.

J Pharmacol Exp Ther. 2002 Feb;300(2):361-6. Review.

2.

Effects of aging and caloric restriction on hepatic drug metabolizing enzymes in the Fischer 344 rat. II: Effects on conjugating enzymes.

Leakey JA, Cunny HC, Bazare J Jr, Webb PJ, Lipscomb JC, Slikker W Jr, Feuers RJ, Duffy PH, Hart RW.

Mech Ageing Dev. 1989 May;48(2):157-66. Review.

PMID:
2500570
3.

The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

Hines RN, McCarver DG.

J Pharmacol Exp Ther. 2002 Feb;300(2):355-60. Review.

4.

Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues.

Toussaint C, Albin N, Massaad L, Grunenwald D, Parise O Jr, Morizet J, Gouyette A, Chabot GG.

Cancer Res. 1993 Oct 1;53(19):4608-12.

PMID:
8402635
5.

Tissue distribution of drug-metabolizing enzymes in humans.

Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB.

Xenobiotica. 1988 Jul;18(7):849-56.

PMID:
3140501
6.

Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.

Albin N, Massaad L, Toussaint C, Mathieu MC, Morizet J, Parise O, Gouyette A, Chabot GG.

Cancer Res. 1993 Aug 1;53(15):3541-6.

8.

Induction of phase I, II and III drug metabolism/transport by xenobiotics.

Xu C, Li CY, Kong AN.

Arch Pharm Res. 2005 Mar;28(3):249-68. Review.

PMID:
15832810
9.
10.

Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver.

el Mouelhi M, Didolkar MS, Elias EG, Guengerich FP, Kauffman FC.

Cancer Res. 1987 Jan 15;47(2):460-6.

11.
12.

Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo.

Ribrag V, Massaad L, Janot F, Bissery MC, Parise O Jr, Gouyette A, Chabot GG.

Leuk Res. 1994 Nov;18(11):829-35.

PMID:
7967709
13.

Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat.

Meinl W, Sczesny S, Brigelius-Flohé R, Blaut M, Glatt H.

Drug Metab Dispos. 2009 Jun;37(6):1179-86. doi: 10.1124/dmd.108.025916.

14.

Effect of long term iron deficiency on the activities of hepatic and extra-hepatic drug metabolising enzymes in Fischer rats.

Rao NJ, Jagadeesan V.

Comp Biochem Physiol B Biochem Mol Biol. 1995 Jan;110(1):167-73.

PMID:
7858940
15.

[Role of monoxygenases in the metabolism of drugs in the human fetus and newborn infant].

Cresteil T, Leroux JP.

Arch Fr Pediatr. 1982 Aug-Sep;39(7):463-70. Review. French.

PMID:
6816186
17.

Genetic contribution to variable human CYP3A-mediated metabolism.

Lamba JK, Lin YS, Schuetz EG, Thummel KE.

Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. Review.

PMID:
12406645
18.

Development of phase II xenobiotic metabolizing enzymes in differentiating murine clara cells.

Fanucchi MV, Buckpitt AR, Murphy ME, Storms DH, Hammock BD, Plopper CG.

Toxicol Appl Pharmacol. 2000 Nov 1;168(3):253-67.

PMID:
11042098
19.

Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.

Rushmore TH, Kong AN.

Curr Drug Metab. 2002 Oct;3(5):481-90. Review.

PMID:
12369894
20.
Items per page

Supplemental Content

Support Center